Bioavailability Study for New Atorvastatin Formulation

Completed · Phase 4

Conditions studied: Hypercholesterolemia

In brief

The purpose of this study is to estimate the relative bioavailability of the commercial tablet with one prototype extemporaneous preparation suspension formulation, to assist with internal decision making on formulation development.

Key facts

Study ID

NCT00844376

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

12

Starts

2008-02-01

Expected to finish

2008-03-01

Last updated by the study team

2021-03-10

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and/or female subjects
• Body Mass Index (BMI) of approximately 18 to 30 kg/m2

You may not qualify if…

• Any condition possibly affecting drug absorption
• A positive urine drug screening

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.